CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytomX Therapeutics reports robust financials and strategic pipeline advancements

CytomX Therapeutics showcased strong financial performance, with a focus on advancing key therapeutic programs and collaborations with industry partners. The company's strategic capital allocation supports pipeline development, while challenges include program prioritization and industry competition. Opportunities for growth exist in advancing pipeline milestones and leveraging collaborations for innovation.

CytomX reports robust Q1 earnings, advances pipeline with key partners

CytomX Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2023
The company's strategic collaborations and focus on innovation position it for future growth
Balancing expenses, regulatory milestones, and clinical progress are key challenges and opportunities
Overall, CytomX is well-positioned to drive value through its transformative therapies

CytomX advances pipeline and partnerships, poised for growth in oncology

CytomX Therapeutics demonstrated strong performance, financial stability, and strategic partnerships in Q2 2023, signaling a promising outlook for future growth.
The company's focus on localized therapies, leadership team strength, and diverse pipeline underscore its competitive position in the biopharmaceutical industry.
While facing challenges in a competitive landscape, CytomX has opportunities for growth through innovative programs, partnerships, and alignment with industry trends.

CytomX Therapeutics reports strong Q3 earnings and outlines strategic roadmap

CytomX Therapeutics showcased solid financial performance in Q3 2023 with revenue of $26.4 million and prudent cost management.
The company's focus on cancer medicines and pipeline advancements position it well for future growth and market competitiveness.
While facing challenges in data updates and cost balancing, strategic milestones and opportunities for collaborations offer avenues for expansion.
Overall, CytomX Therapeutics remains well-positioned in the oncology sector with a strong cash position and promising pipeline candidates.

CytomX posts robust Q4 results, poised for growth in 2024

CytomX Therapeutics delivered a strong performance in Q4 2023, showcasing financial stability, progress on its Probody platform, and strategic partnerships to drive innovation.
While facing challenges in clinical development and partnership dynamics, the company's strengths in product pipeline diversity and financial management offer a solid foundation for future growth.
With exciting opportunities ahead, including upcoming data readouts and advancements in immunotherapy, CytomX is well-positioned to capitalize on its expertise in antibody masking and conditional activation.

CytomX reports positive Phase Ia data for CX-904 therapy

CytomX Therapeutics showcases strong performance with promising drug data.
Company's financial stability and innovative platform position it well for growth.
Challenges in translating research to clinical outcomes and predicting patient responses.
Opportunities lie in expanding drug potential, exploring combination strategies, and addressing assay challenges.

CytomX reports strong Q3 results, advances promising oncology therapies

CytomX Therapeutics delivered solid financial performance in Q3 2024 with a focus on key oncology programs.
The company's Probody platform shows promise in addressing unmet medical needs in various cancers.
Challenges lie in optimizing dose escalation, enrollment, and expansion of therapies to maximize impact.
Strategic partnerships and disciplined capital allocation position CytomX for future growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an additional 2,142,857 shares of common stock, pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with CytomX's previously announced underwritten public offering of common stock. A total of 16,428,571 shares of common stock at a price to the public of $7.00 have now been sold by CytomX in the offering, resulting in net proceeds to CytomX of approximately $107.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. All shares in the offering were sold by CytomX.

CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (NASDAQ:CTMX).

Steven Cohen Snaps Up Stake in CytomX Therapeutics

Editas Medicine

Inovio Pharmaceuticals

All four biotechs announced the pricing of stock offerings.

Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock at a price to the public of $7.00 per share, for gross proceeds of $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by CytomX. All shares are being offered by CytomX. In addition, CytomX has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of its common stock at the public offering price, on the same terms and conditions.

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are to be offered by CytomX.

CytomX Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 14th at 11:40 a.m. ET.

CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company's board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and corporate strategy.

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

Axcella Health Inc

Kaleido Biosciences Inc

Magenta Therapeutics Inc

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 4 Sizzling Biotech Stocks to Buy That Are Under $10

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in November.

CytomX Therapeutics to Present at Upcoming Investor Conferences

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2020 Results - Earnings Call Transcript

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 11.11% and 1.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q3 Loss, Tops Revenue Estimates

Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT- -Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT-

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research

CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

SOUTH SAN FRANCISCO, Calif., Sept.  02, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in September.

CytomX Therapeutics to Participate in Upcoming Healthcare Conferences

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the 2020 Wedbush PacGrow Virtual Healthcare Conference.

CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Earnings Expected to Grow: Should You Buy?

NEW YORK, July 20, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. between May 17, 2018, and May 13, 2020, inclusive (the "Class Period"), of the important July 20, 2020 lead plaintiff deadline in.

CTMX FINAL DEADLINE: ROSEN, A TRUSTED AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important July 20 Deadline in Securities Class Action - CTMX

New York, New York--(Newsfile Corp. - July 20, 2020) -  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc.

CTMX Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against CytomX Therapeutics, Inc. and Lead Plaintiff Deadline: July 20, 2020

Los Angeles, California--(Newsfile Corp. - July 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics, Inc.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 4 Red-Hot Biotech Stocks to Buy Under $10

New York, New York--(Newsfile Corp. - July 17, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc.

Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm

Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics, Inc.

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - July 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc.

CTMX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2020 in the Class Action Filed on Behalf of CytomX Therapeutics, Inc. Limited Shareholders

News for CytomX Therapeutics Stock (CTMX)